 The MMPREDICT study is a Horizon 2020 project started in November 2016 and is funded by the European Commission on the Horizon 2020 program. It is a team of two clinical partners. We have the Erasmus Medical Center and the University of Turin. We have a biotech company, Scott and the X. We have the Erasmus University, the economic partner within our team. And we have the Miloma patient's Europe as a partner representative in the project. We aim to develop a diagnostic tool which can predict the most effective treatment for each Miloma patient. Scott and the X is a specialized company in the development and validation of diagnostic tests. We have put already a test on the market for Miloma, the MMPREDICT. And it's a test which can distinguish patients from in a high risk group or a standard risk group. Currently we're now focusing more on the treatment side. If we can also predict which treatment is best for which patients and that's where we can implement our knowledge in the development of such tests. So we will measure genetic information from different multiple Miloma patients throughout Europe. We have recruited 800 patient samples and we hope to get some genetic information and from these patients look at their treatment and see if there's any correlation between those. In that sense we can implement this in the future to predict which patients is most suitable for which treatment. We hope that every patient gets the optimal treatment they deserve and in that sense focus on the most effective treatment for each individual Miloma patients. Also we hope to provide this and improve the care of these patients so reduce the side effect and directly get the right treatment for these patients.